Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 01 tags : Treatment save search
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
Published: 2022-12-01 (Crawled : 23:00) - biospace.com/
COCP | $1.5559 -0.39% -1.39% 0
|
Health Technology
|
| O: -1.46%
H: 9.17%
C: 5.19%
cc-4234 treatment pharma antiviral potential influenza cc-42344
Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Published: 2022-12-01 (Crawled : 23:00) - prnewswire.com
RIGL | $1.125 -1.32% -1.33% 0
|
Health Technology
|
| O: 37.32%
H: 5.84%
C: -11.27%
treatment fda leukemia approval acute myeloid leukemia
Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis
Published: 2022-12-01 (Crawled : 23:00) - biospace.com/
VTYX | $4.24 300
|
Manufacturing
|
| O: -0.38%
H: 3.22%
C: 2.29%
vtx958 treatment trial psoriasis
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
Published: 2022-12-01 (Crawled : 19:00) - biospace.com/
NTLA | $21.17 -1.67% -1.75% 1.5K
|
Health Technology
|
| O: -6.84%
H: 0.13%
C: -4.46%
spvn06 treatment application
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
SLRX | $0.508 1.4% 1.18% 0
|
Commercial Services
|
| O: 1.04%
H: 1.79%
C: -6.15%
treatment pharmaceuticals seclidemstat trial phase 1
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
NVCT | $6.71 1.82% 1.86% 0
|
|
| O: 1.9%
H: 8.41%
C: 1.34%
nxp800 treatment fda designation grants fast track designation
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease
Published: 2022-12-01 (Crawled : 13:20) - igcinc.us
IGC 4 | $0.4379 -0.25% 62K
|
Health Technology
|
| O: 7.49%
H: 3.07%
C: -0.35%
treatment dementia trials drug candidate disease alzheimer’s phase 2
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
Published: 2022-12-01 (Crawled : 13:00) - prnewswire.com
CTXR | $0.6834 -4.62% 72K
|
Health Technology
|
| O: 0.85%
H: 8.47%
C: 4.24%
treatment drug t-cell application license food
MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference
Published: 2022-12-01 (Crawled : 13:00) - prnewswire.com
MNMD | $8.46 -4.62% -4.97% 910
|
n/a
|
| O: 0.39%
H: 8.59%
C: 4.88%
treatment conference health
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
Published: 2022-12-01 (Crawled : 13:00) - prnewswire.com
ONCY | $1.05 -0.94% -3.35% 1.5K
|
Health Technology
|
| O: 5.11%
H: 23.24%
C: 14.59%
biotech treatment fda designation cancer pancreatic fast track designation
Boosting ESG Profile in Water and Wastewater Treatment Industry: Astra ESG Solutions
Published: 2022-12-01 (Crawled : 11:00) - prnewswire.com
DD | News | $73.29 -0.91% 36K
|
Process Industries
|
| O: -0.23%
H: 0.64%
C: 0.1%
water treatment solutions esg
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
ILAG | $0.669 23.89% 13M
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.